Search

Author/Creator Kebenko, M.

1. Results from the primary analysis of a 30 patient extension of the GATTO study, a phase Ib study combining the anti-MUC1 Gatipotuzumab (GAT) with the anti-EGFR Tomuzotuximab (TO) or Panitumumab in patients with refractory solid tumors. (October 2020)

Authors:
Macchini, M.; Garralda, E.; Fiedler, W.; Del Conte, G.; Rolling, C.; Kebenko, M.; Klinghammer, K.F.; Ahrens-fath, I.; Habel, B.; Baumeister, H.; Zurlo, A.; Ochsenreiter, S.
Journal:
European journal of cancer
Issue:
Volume 138(2020)Supplement 2
Page Start:
S5
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search